Project Grant R35GM166541
- The National Institute of General Medical Sciences awarded $1.688 million to Pacific Northwest National Laboratory, a division of Battelle Memorial Institute, on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a multimodal measurement platform for unambiguous lipid identification. The recipient will build a high-resolution ion mobility-mass spectrometry (IM-MS) system designed to distinguish free fatty acids and lipid isomers in complex...
- The National Institute of General Medical Sciences awarded Brigham Young University $558,383 on July 1, 2026 under the Biomedical Research and Research Training program (CFDA 93.859) to optimize therapeutic protein pegylation by integrating coarse-grain molecular simulation with cell-free protein synthesis and site-specific functionalization. The work addresses a fundamental limitation in protein therapeutics: polyethylene glycol (PEG) attachment, which improves drug half-life and immune...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Brigham Young University $405,295 on July 8, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and refine the Phosphorylation Integrated Thermal Shift Assay (PITSA) for identifying functional roles of protein post-translational modifications at proteome scale. The award funds research to expand PITSA's capability...
- The National Institute of General Medical Sciences awarded $502,372 to Massachusetts Institute of Technology on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop selective, catalytic isomerization reactions that convert simple organic building blocks into complex organic molecules relevant to biomedical research. The work encompasses stereocenter editing—precise interconversion of stereoisomeric molecules at late synthetic stages to enable...
- The National Institute of General Medical Sciences awarded Brigham Young University $442,140 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop quantum-chemical and data science approaches for modeling multimetallic transition metal catalyzed organic reactions. The work focuses on two reaction types: metal hydrogen atom transfer reactions for alkene functionalization and cross-coupling reactions relevant to drug discovery. The project will...
- The National Institute of General Medical Sciences awarded $2,843,142 to Battelle Memorial Institute's Pacific Northwest National Laboratory on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a next-generation ultra-high resolution ion mobility spectrometer platform for metabolomics research. The project will deliver an ion mobility spectrometer with ultra-high resolution and sensitivity to detect small changes in metabolite structure, coupled...
- The National Institute of General Medical Sciences awarded $565,993 to Regents of the University of Michigan on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop next-generation native ion mobility-mass spectrometry (NIM-MS) methods for characterizing biotherapeutics, including protein and nucleic acid therapeutics. The project focuses on creating rapid, droplet-based enzymatic chemistries and collision-induced unfolding (CIU) approaches to assess...
- The National Institute of General Medical Sciences awarded Yale University $304,970 under the Biomedical Research and Research Training program (CFDA 93.859) on June 1, 2026, to develop next-generation mass spectrometry platforms for analyzing membrane protein complexes and their lipid environments at molecular and nanoscale resolution. The award funds three independent projects. Project 1 develops a native mass spectrometry platform to capture heteromeric complexes of membrane and soluble...
- The National Institute of General Medical Sciences awarded Battelle Memorial Institute's Pacific Northwest National Laboratory $492,167 on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a high-throughput multiomic platform for simultaneous single-cell profiling of proteins, transcripts, and metabolites. The platform integrates novel chemistry, advanced mass spectrometry, and automated nanodroplet processing to analyze thousands of individual...
- Federal Grant Award Summary Brigham Young University received a $439,203 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded August 15, 2025, with a completion date of August 14, 2028. The project, titled "Using Catalyst Speciation to Control Reactivity and Address Longstanding Challenges in Cross Coupling Reactions," focuses on developing and optimizing 2-phosphinoimidazole...
The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Brigham Young University $406,576 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an analytical platform for simultaneous separation, identification, and quantification of lipid isomers using non-covalent chemistry-based enhancement of tandem ion mobility-mass spectrometry. The research integrates non-covalent chemical modification strategies with cyclic ion mobility spectrometry coupled to tandem mass spectrometry to enable gas-phase separation of lipid isomers with enhanced resolution. The work addresses the current lack of analytical technologies with sufficient resolution and throughput to distinguish and quantify lipid isomers in complex biological samples, despite evidence that structural variations in isomers—such as double-bond position, stereochemistry, or glycosidic linkage—profoundly influence biological activity and disease relevance. Examples include glycosphingolipid isomers glucosylceramide and galactosylceramide associated with Gaucher and Krabbe diseases, respectively, and positional isomers of unsaturated lipids linked to breast cancer. The research team has demonstrated that non-covalent modifications enable isomer separation, identification, and relative quantification in small molecule systems and is extending these methods to biologically relevant lipid mixtures, including glycosphingolipid stereoisomers. Recent implementation of gas-phase ion/ion reactions within the platform further expands the chemical space accessible for isomer discrimination. Work is performed in Provo, Utah. The period of performance runs through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $406.6k | 8/14/26 |